-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 27, 2021, Takeda announced the exercise of its option to acquire GammaDelta Therapeutics
.
GammaDelta's γδ T cell therapy platform will be obtained, including an allogeneic cell immunotherapy project based on blood and tissue-derived γδ T cell subgroup Vδ1+ cells
.
γδT lymphocytes, αβT lymphocytes and B lymphocytes together form the key "guard" of the adaptive immune system
.
These cells can recognize dysregulated molecular patterns in stress, pathogen infection, or cancerous cells, and respond quickly to maintain homeostasis
.
Vδ1+T cells belong to a subgroup of γδT cells, which are usually found in skin and colon tissues, and there are also lower levels in the blood.
Compared with Vδ2+T lymphocytes that recognize bacterial phosphoantigens, studies have shown that these cells are acceptable Autologous stem cell transplantation (ASCT) for blood cancer patients provides special benefits in terms of long-term survival
▲The advantages of Vδ1+CAR-T cell therapy (picture source: GammaDelta official website)
GammaDelta isolates Vδ1+T cells from skin and other tissues or blood, and expands them.
It can continue to further enhance the characteristics of Vδ1+T cells through cell and genetic engineering
.
For example, chimeric antigen receptor (CAR) and other transgenes are introduced into Vδ1+ T cells to target cancer and other serious diseases
.
"We are committed to developing ready-to-use cell therapies for the benefit of the majority of patients
.
" said Dr.
Christopher Arendt, head of the cell therapy field at Takeda Oncology.
Reference materials:
[1] Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors.
Retrieved October 27, 2021, from https:// -GammaDelta-Therapeutics-to-Accelerate-Development-of-Allogeneic-%CE%B3%CE%B4T-Cell-Therapies-Addressing-Solid-Tumors[1] Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors.
Retrieved October 27, 2021, from https:// -GammaDelta-Therapeutics-to-Accelerate-Development-of-Allogeneic-%CE%B3%CE%B4T-Cell-Therapies-Addressing-Solid-Tumors
